Refractory Gout
Conditions
Interventions
Control Group:Febuxostat 20mg qd po
Experimental Group:Oral febuxostat 20 mg/day Hemoperfusion once a week for three weeks
Sponsors
The Affiliated Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Male or female, 18 years old=360µmol/L; (2) Gout attacks >=2 times/year despite standardized treatment; (3) patients with multiple and/or progressive tophi); 3. Patients with serum uric acid >=480 µmol/L 2 weeks after elution; 4. Presence of at least one tophi detectable by imaging examination; 5. Subjects voluntarily participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Patients with hyperuricemia secondary to other diseases, such as blood diseases (including leukemia, multiple myeloma or other malignant tumors), chronic poisoning, increased blood uric acid production caused by chronic kidney disease, or disorders of uric acid excretion; 2. Those who are expected to undergo tophi surgery during the study period or need to use other blood purification treatments at the same time; 3. Patients with coagulation dysfunction, severe bleeding tendency (PT value greater than the upper limit of normal value for more than 6s and accompanied by bleeding, or APTT value greater than 1.5 times of the upper limit of normal value and accompanied by bleeding; 4. Those who have a history of allergy to heparin, sodium citrate, colchicine, febuxostat, plasma separator, membrane or tubing of adsorption column; 5. Receiving imidazothioprine, azathioprine, chophylline, mercaptopurine, or thiazide diuretics, and need to continue to use during the trial; 6. Those with severe liver impairment (Child-Pugh grade C) or accompanied by bone marrow insufficiency; 7. Severe active hemorrhage or systemic circulatory failure that is difficult to correct with DIC or drugs, cardiac or cerebral infarction in unstable period, intracranial hemorrhage or severe cerebral edema with cerebral herniation, mental disorder and unable to cooperate with treatment, etc.; 8. Pregnant or lactating females; 9. Those who have participated in any drug clinical trial within 3 months before screening, or have participated in a medical device clinical trial within 1 month; 10. Any other reasons that the investigator believes may affect the efficacy and/or safety evaluation of this study and are not suitable for participating in this clinical trial (including but not limited to those who are judged by the investigator to have poor compliance with the subject, or live far away and cannot be followed up on schedule).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Uric Acid; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tophi volume; | — |
Countries
China
Contacts
Public ContactLi Changgui
The Affiliated Hospital of Qingdao University
Outcome results
None listed